Patient engagement is an increasingly important aspect of successful clinical trials. Over the past decade, as patient group involvement in clinical trials has continued to increase and diversify, the Clinical Trials Transformation Initiative has not only recognized the crucial role patients play in improving the clinical trial enterprise but also made a deep commitment to help grow and shape the emerging field of patient engagement. This article describes the evolution of patient engagement including the origins of the patient engagement movement; barriers to successful engagement and remaining challenges to full and valuable collaboration between patient groups and trial sponsors; and Clinical Trials Transformation Initiative's role in influencing the field through organizational practices, formal project work and resulting recommendations, and external advocacy efforts.
Introduction
In recent years, patient engagement in clinical trials has emerged as an increasingly important aspect of successful clinical trials. Across all involved groups-sponsors, academics, regulators, and patients-the primary goal of clinical trials is to more rapidly answer research questions and deliver safe, effective treatments to patients: patient engagement is central to accomplishing this goal. From the 2007 inception of the Clinical Trials Transformation Initiative's (CTTI) multi-stakeholder engagement model, patients have been included as valued partners, serving on governance committees and project teams. Over the past decade, as patient group involvement in clinical trials has continued to increase and diversify, CTTI leadership has not only recognized the crucial role patients play in improving the clinical trial enterprise but also made a deep commitment to help grow and shape the emerging field of patient engagement.
Defining engagement
Patient engagement may be defined as an effort to extend the benefits of patient insight and experiences, as well as desires and preferences, in both the research and development process, or, ''from bench to bedside'' through collaborative relationships, in order to conduct more efficient and patient-centered, high-quality research. While patients may seem like obvious partners, their involvement is relatively new in the history of clinical trials. In 1988, activists from ACT UP 1 chained themselves to the fence at the U.S. Food and Drug Administration (FDA) as part of an orchestrated publicity campaign to demand a seat at research and regulatory tables to ensure the needs of patients, particularly related to perceptions of risk versus benefit, were front and center. The foundational work of the HIV/ AIDS community, and later breast cancer organizations, demonstrated the powerful impact of the patient voice and led to patient groups taking an increasingly active role in the clinical trials enterprise. Patient-driven research activities have ranged from pre-discovery funding for development and acquisition of animal models and cell lines, all the way to post-market study design. They include collecting natural history information; involvement in endpoint selection, protocol design, consent development, clinical trial recruitment, and retention strategies; design of post-market safety studies; and dissemination of trial findings. In essence, the new research-focused patient groups strategically engage their patient communities and deploy their assets and capabilities to de-risk clinical trials and medical product development.
Barriers to engagement
In spite of the growing list of activities in which patient groups are collaborators, CTTI has discovered that many barriers remain to patient engagement. Prior to 2007, no best practices for engagement existed beyond nebulous recommendations, such as use ''good communication'' or ''be trustworthy and transparent in relationships.'' Furthermore, patient group interests, capabilities, and assets vary greatly, as do sponsor cultures, perceptions of value, and processes for establishing productive clinical trial partnerships. This organizational heterogeneity results in a lack of clarity surrounding how to optimize relationships and best capture the patient voice in clinical trials: who should be engaged, when should they be engaged, and in what capacity? Engagement can be complex and must avoid conflict of interest or promotion of investigational products: an aspect of engagement that has vexed regulators, patient organizations, and sponsors alike. Newer initiatives such as FDA's Patient-Focused Drug Development 2 program have opened opportunity for greater patient involvement in medical product development.
Practices for increasing patient voice within CTTI
CTTI is dedicated to moving the needle on increasing patient voice. In 2012, to this end, CTTI added a Director of Stakeholder Engagement to its leadership team, a role in which I served from 2012 to 2016. My credentials include experience as a founder and president of a patient advocacy organization, serving as an FDA patient representative, and being a patient in a clinical trial aborted for slow and low enrollment. This set of credentials contrasts with those in engagement leadership positions within other organizations. For example, industry most often appoints medical doctors to the role of Chief Patient Engagement Officer advocating on behalf of patients.
In 2013, to further understand issues from the patient perspective in an effort to improve the quality and efficiency of research, CTTI created a Patient Leadership Council (PLC) comprising 18 patient thought leaders and key opinion leaders from patientdriven research foundations. Formation of the PLC grew the patient voice at CTTI, which already represented industry sponsors, regulators, academics, clinical research organizations, institutional review board representatives, individual patient representatives (selected through an open national application process), and representatives of federal agencies, among others, on the CTTI steering committee. Initially, PLC members convened monthly under a roundtable model to facilitate dialog surrounding barriers to patient engagement with a goal of introducing project ideas to CTTI membership. PLC members were also invited and offered travel support to attend bi-annual CTTI steering committee meetings, where representatives from CTTI member organizations provide input into decisions about CTTI priorities, projects, and recommendations. It quickly became apparent, however, that sequestration of the PLC as a unique entity apart from CTTI's steering committee did not afford Council members an equal voice. Soon after launch, the PLC recommended it be disbanded and fully integrated into the steering committee as regular member organizations, including paying CTTI membership fees, to maximize co-learning and fully integrate the patient perspective into the diverse and candid conversations surrounding clinical trials characteristic of the steering committee. Finally, the PLC introduced a project idea that was voted into acceptance by CTTI membership: to generate evidence on successes and failures in engaging patient groups in clinical trials and develop recommendations on best practices for effective engagement. In 2014, upon acceptance of the PLC member recommendations, a multi-stakeholder project team was formed with equal representation of patient leadership, and the Patient Groups & Clinical Trials Project 3 was launched. Importantly, as the role and structure of the PLC changed within CTTI, and interest in similar models of patient engagement grew in other organizations, CTTI further helped to shape the field by supporting staff time to broadly share experiences and to establish and disseminate best practices for the emerging field of patient engagement. In parallel, CTTI leadership catalyzed numerous dialogs with umbrella and multistakeholder organizations with similar objectives to take stock of the clinical trials ecosystem, build consensus on priority issues, explore the strengths and needs of each organization, avoid duplication that could dilute finite resources, and develop supportive relationships to achieve together what could not be achieved alone. In 2016, to further support the important contributions by representatives of the patient community to CTTI activities, CTTI began providing monetary compensation to patient representatives for time spent on those activities, in addition to travel support for CTTI meetings. Through the above-discussed avenues, CTTI has deeply invested in responsibly shepherding a fledging field through its adolescence.
The CTTI Patient Groups & Clinical Trials Project
The Patient Groups & Clinical Trials Project 3 began with a literature review and was followed by a survey to gather the perceptions of three distinct stakeholder groups-patient groups, industry sponsors, and academia-about (1) patient group organizational characteristics, (2) engagement activities or clinical trial services being provided by patient groups, (3) perceived barriers to productive partnerships, and (4) perceived value of partnerships. Next, more than 30 qualitative interviews were performed with engagement experts from each stakeholder group to more deeply explore successes and failures. The project team then brought this evidence into a meeting with 62 experts and national leaders from industry, academia, patient groups, FDA, and National Institutes of Health (NIH) for review, discussion, consensus building, and development of recommendations on best practices. Agreed upon best practices were released in October 2015 4, 5 with accompanying tools to support step-bystep practical implementation (Figure 1 ). These recommendations have since been touted as a roadmap for patient groups and research sponsors engaged in strategic planning, the process of gaining buy-in from leadership, and making investments in assets or operations. CTTI project team members have presented the Patient Groups & Clinical Trials Project recommendations 4 over 50 times in the past 2 years, and the recommendations have also been adopted by multi-stakeholder consortia outside the United States.
The Patient Groups & Clinical Trials Project 3,5 did not end with the release of recommendations: CTTI continues to put great energy into working with stakeholders to promote adoption and learn about remaining barriers. In response to assessment of remaining barriers, the project team undertook a second phase of work and went on to develop and publish a conceptual model to assess the financial value of patient engagement, which has been key to establishing return on investment. 6 Additional work continues to further understand the value of specific engagement methods and to develop a library of case studies.
Conclusion
CTTI's thoughtful approach to the field of patient engagement has allowed stakeholders with vested interests to shine a light on barriers to high-quality, efficient clinical trials. CTTI has led the way in developing solutions, while supporting stakeholders with an incubator for candid dialog, rigorous scientific support, and resources with which to affect credible change. While CTTI, as a public-private partner of FDA, is primarily focused on the US landscape, its work and approach have undoubtedly had a global impact, touching the lives of patients in clinical trials around the world and paving the way for greater engagement of patient partners in the clinical trials enterprise.
